ReviewCancer cell international2025
Redefining cancer care: harnessing circulating tumor cells' potential for improved diagnosis and prognosis.
Review in Cancer cell international, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- Artificial intelligence and multi-omics integration in liquid biopsy for genitourinary cancers: a systematic scoping review.International urology and nephrology · 2026Review
- Circulating Tumour Cells as Potential Biomarkers for Oral Squamous Cell Carcinoma.Molecules (Basel, Switzerland) · 2026Review
- Circulating Tumor Cells: Isolation, Preclinical Models, and Clinical Applications for Personalized Cancer Therapy.Biomolecules · 2026Review
- Direct detection of rare circulating tumor cells in peripheral blood mononuclear cells by scRNA seq: Spike-in strategy based feasibility study.The journal of liquid biopsy · 2026Article
- Liquid Biopsy and Multi-Omic Biomarkers in Breast Cancer: Innovations in Early Detection, Therapy Guidance, and Disease Monitoring.Biomedicines · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Circulating tumor cells (CTCs) represent a small but clinically relevant pool of cells from tumors that can be sampled with minimally-invasive liquid biopsy procedures. They are dynamic and poorly-defined transition state of cancer cells, offering vital insights into tumor progression and metastasis. CTC frequencies are emerging as real-time means for therapeutic monitoring and patient stratification across different malignancies. However, their detection, isolation, and characterization pose a major challenge leading to variation in their counts that limit their clinical utility. This review delves into the key parameter, CTC counts, which often correlate with clinical outcomes. Further, it highlights the significance of culturing CTCs in vitro and employing CTC-derived xenograft (CDX) models to obtain in vivo insights into tumor biology, treatment efficacy, and personalized medicine strategies. The review examines the role of CTCs as diagnostic, prognostic, and therapeutic monitoring marker for different cancers. It also discusses the opportunities in CTC-directed clinical utility and associated limitations such as CTC heterogeneity and technological variations among different isolation strategies that hinder their widespread implementation. Hence, it underscores the evolving importance of CTCs in clinical oncology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.